prostate cancer (nmHSPC)
Oncology · 2024–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| enzalutamide Treatment of patients with non-metastatic hormone sensitive prostate cancer (m0HSPC) with high-risk biochemical recurrence (BCR), in combination with androgen… | Mar 2026 | Recommended with restriction | 7 individuals Prostate Cancer Foundation · Port Macquarie Prostate Cancer Support Group |
| enzalutamide Treatment of patients with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence (PSA doubling time ≤9 months), with or… | Nov 2024 | Not recommended | input received Rare Cancers Australia · Medical Oncology Group Australia |
Who spoke
Rare Cancers Australia · Medical Oncology Group Australia · Prostate Cancer Foundation · Port Macquarie Prostate Cancer Support Group
What the PBS pays
$180M in government benefit over 2024–25, across 52,324 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| enzalutamide | $179.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.